JP2005532372A - 脳脊髄液へのアセチルコリンエステラーゼ阻害薬の投与 - Google Patents

脳脊髄液へのアセチルコリンエステラーゼ阻害薬の投与 Download PDF

Info

Publication number
JP2005532372A
JP2005532372A JP2004517563A JP2004517563A JP2005532372A JP 2005532372 A JP2005532372 A JP 2005532372A JP 2004517563 A JP2004517563 A JP 2004517563A JP 2004517563 A JP2004517563 A JP 2004517563A JP 2005532372 A JP2005532372 A JP 2005532372A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
acetylcholinesterase inhibitor
inhibitor
mammal
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004517563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532372A5 (enExample
Inventor
クワ，スティーブン・シー
Original Assignee
ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド filed Critical ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド
Publication of JP2005532372A publication Critical patent/JP2005532372A/ja
Publication of JP2005532372A5 publication Critical patent/JP2005532372A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004517563A 2002-05-21 2003-05-19 脳脊髄液へのアセチルコリンエステラーゼ阻害薬の投与 Withdrawn JP2005532372A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38212202P 2002-05-21 2002-05-21
PCT/US2003/015653 WO2004002402A2 (en) 2002-05-21 2003-05-19 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid

Publications (2)

Publication Number Publication Date
JP2005532372A true JP2005532372A (ja) 2005-10-27
JP2005532372A5 JP2005532372A5 (enExample) 2006-04-06

Family

ID=30000415

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004517563A Withdrawn JP2005532372A (ja) 2002-05-21 2003-05-19 脳脊髄液へのアセチルコリンエステラーゼ阻害薬の投与

Country Status (9)

Country Link
US (1) US20030225031A1 (enExample)
EP (1) EP1505971A2 (enExample)
JP (1) JP2005532372A (enExample)
AU (1) AU2003269874A1 (enExample)
CA (1) CA2482161A1 (enExample)
IL (1) IL163731A0 (enExample)
NZ (1) NZ535192A (enExample)
WO (1) WO2004002402A2 (enExample)
ZA (1) ZA200407420B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086493A1 (ja) * 2006-01-27 2007-08-02 Asahi Kasei Pharma Corporation 経鼻投与用薬剤
JP2014520529A (ja) * 2011-06-27 2014-08-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病を示すマイクロｒｎａバイオマーカー
JP2016515575A (ja) * 2013-03-24 2016-05-30 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP2017530195A (ja) * 2014-10-03 2017-10-12 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
WO2018092765A1 (ja) * 2016-11-15 2018-05-24 学校法人同志社 経鼻投与用医薬組成物
US11559533B2 (en) 2019-12-16 2023-01-24 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
WO2005013906A2 (en) * 2003-08-08 2005-02-17 Sri International pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT
DE10340740A1 (de) * 2003-09-04 2005-03-31 Degussa Food Ingredients Gmbh Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
CN1961879B (zh) * 2005-11-09 2011-11-30 上海医药工业研究院 组成石杉碱甲鼻用原位凝胶喷雾剂的药物组合物、其制备方法及用途
WO2007078879A2 (en) * 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
JP5122791B2 (ja) * 2006-09-22 2013-01-16 石川金属株式会社 はんだ付け用フラックスおよびソルダペーストとヤニ入りはんだ
US8969402B2 (en) * 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
DE102006056783A1 (de) * 2006-12-01 2008-06-05 Lts Lohmann Therapie-Systeme Ag Zubereitung zur transdermalen Verabreichung von Galanthamin
KR101408488B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법
WO2008088039A1 (ja) * 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法
WO2008148515A1 (en) * 2007-06-05 2008-12-11 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
RU2483729C2 (ru) * 2008-05-30 2013-06-10 Нитто Денко Корпорейшн Чрескожно абсорбируемый препарат
EP2279739B2 (en) * 2008-05-30 2018-02-28 Nitto Denko Corporation Donepezil-containing patch preparation and packaging thereof
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
WO2014039920A1 (en) * 2012-09-10 2014-03-13 Lewin Matthew R Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
WO2015148480A1 (en) 2014-03-25 2015-10-01 Emicipi Llc Treatment of rett syndrome
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
CN107375945B (zh) * 2017-08-29 2020-10-13 沈阳药科大学 一种多奈哌齐环糊精包合物及含有此包合物的口服速溶膜剂
CN110507610A (zh) * 2019-07-24 2019-11-29 西北农林科技大学 一种含有维生素d的纳米乳药物及其制备方法
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
CN114432495B (zh) * 2021-12-09 2022-09-20 中国人民解放军空军军医大学 一种可促进内源性骨再生的生物材料及其制备方法和应用
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN116602918A (zh) * 2023-02-24 2023-08-18 中国药科大学 一种多奈哌齐鼻喷剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69215108T2 (de) * 1991-08-10 1997-03-20 Hisamitsu Pharmaceutical Co Phenylalkansäurederivat, seine herstellung und die trennung seiner optischen isomere
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP2003514564A (ja) * 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007086493A1 (ja) * 2006-01-27 2009-06-25 旭化成ファーマ株式会社 経鼻投与用薬剤
WO2007086493A1 (ja) * 2006-01-27 2007-08-02 Asahi Kasei Pharma Corporation 経鼻投与用薬剤
JP2014520529A (ja) * 2011-06-27 2014-08-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病を示すマイクロｒｎａバイオマーカー
JP2016214256A (ja) * 2011-06-27 2016-12-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病を示すマイクロｒｎａバイオマーカー
US11071742B2 (en) 2013-03-24 2021-07-27 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2016515575A (ja) * 2013-03-24 2016-05-30 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US12186330B2 (en) 2013-03-24 2025-01-07 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US10251896B2 (en) 2013-03-24 2019-04-09 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP7080944B2 (ja) 2013-03-24 2022-06-06 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
US10857162B2 (en) 2013-03-24 2020-12-08 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP2021008473A (ja) * 2013-03-24 2021-01-28 アミーリクス・ファーマシューティカルズ・インコーポレイテッド 細胞生存率を向上させるための組成物およびその使用方法
JP2017530195A (ja) * 2014-10-03 2017-10-12 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2022003100A (ja) * 2014-10-03 2022-01-11 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2020090547A (ja) * 2014-10-03 2020-06-11 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP7357571B2 (ja) 2014-10-03 2023-10-06 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
WO2018092765A1 (ja) * 2016-11-15 2018-05-24 学校法人同志社 経鼻投与用医薬組成物
US11559533B2 (en) 2019-12-16 2023-01-24 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12246027B2 (en) 2019-12-16 2025-03-11 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
AU2003269874A1 (en) 2004-01-19
IL163731A0 (en) 2005-12-18
CA2482161A1 (en) 2004-01-08
WO2004002402A2 (en) 2004-01-08
ZA200407420B (en) 2006-06-28
WO2004002402A3 (en) 2004-10-07
US20030225031A1 (en) 2003-12-04
EP1505971A2 (en) 2005-02-16
NZ535192A (en) 2006-05-26

Similar Documents

Publication Publication Date Title
US20030225031A1 (en) Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20060003989A1 (en) Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals
RU2444351C2 (ru) Композиция для лечения ринита и родственных заболеваний и способ ее получения
KR102453781B1 (ko) 알코올 사용 장애의 치료용 조성물, 장치 및 방법
US9980959B2 (en) Method and composition for treating rhinitis
JP2021088575A (ja) Ｇｉ管障害を治療するための方法
WO2024109652A1 (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
US20260021074A1 (en) Methods and compositions for oral pilocarpine liquid
EP1517674B1 (de) Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter cgrp-antagonisten
KR20240006600A (ko) 투약 요법
US11931370B2 (en) Stable pharmaceutical compositions of cyclophosphamide
KR101198201B1 (ko) 비염 치료를 위한 방법 및 조성물
HK1115314B (en) Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060216

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080925